Q1 Earnings Estimate for ZNTL Issued By Wedbush

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Stock analysts at Wedbush issued their Q1 2026 EPS estimates for shares of Zentalis Pharmaceuticals in a research note issued to investors on Tuesday, November 11th. Wedbush analyst R. Driscoll anticipates that the company will earn ($0.32) per share for the quarter. Wedbush currently has a “Neutral” rating and a $4.00 target price on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.42) per share. Wedbush also issued estimates for Zentalis Pharmaceuticals’ Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($0.33) EPS and Q4 2026 earnings at ($0.33) EPS.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its earnings results on Monday, November 10th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.12.

A number of other brokerages also recently issued reports on ZNTL. Leerink Partners reissued a “market perform” rating and issued a $2.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Tuesday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Zentalis Pharmaceuticals in a report on Wednesday, October 8th. Wells Fargo & Company dropped their price target on Zentalis Pharmaceuticals from $6.00 to $5.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 7th. HC Wainwright raised shares of Zentalis Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, August 7th. Finally, Wall Street Zen lowered shares of Zentalis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $5.03.

Zentalis Pharmaceuticals Trading Down 4.3%

Shares of ZNTL opened at $1.34 on Wednesday. The firm’s fifty day simple moving average is $1.54 and its two-hundred day simple moving average is $1.45. Zentalis Pharmaceuticals has a 12 month low of $1.01 and a 12 month high of $4.44. The stock has a market capitalization of $96.66 million, a P/E ratio of -0.65 and a beta of 1.87.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Millennium Management LLC increased its position in shares of Zentalis Pharmaceuticals by 220.6% during the first quarter. Millennium Management LLC now owns 3,069,514 shares of the company’s stock worth $4,881,000 after acquiring an additional 2,111,951 shares in the last quarter. Vanguard Group Inc. lifted its position in Zentalis Pharmaceuticals by 0.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,904,400 shares of the company’s stock valued at $4,386,000 after acquiring an additional 19,768 shares in the last quarter. Acadian Asset Management LLC boosted its stake in Zentalis Pharmaceuticals by 4.7% during the 2nd quarter. Acadian Asset Management LLC now owns 2,799,020 shares of the company’s stock valued at $3,241,000 after purchasing an additional 124,985 shares during the last quarter. Almitas Capital LLC boosted its stake in Zentalis Pharmaceuticals by 5.2% during the 1st quarter. Almitas Capital LLC now owns 1,710,921 shares of the company’s stock valued at $2,720,000 after purchasing an additional 84,025 shares during the last quarter. Finally, Tybourne Capital Management HK Ltd. increased its holdings in Zentalis Pharmaceuticals by 53.7% during the 2nd quarter. Tybourne Capital Management HK Ltd. now owns 1,478,152 shares of the company’s stock worth $1,715,000 after purchasing an additional 516,666 shares in the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.